Projects per year
Personal profile
Research Strategic Pillar
The Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Human Genetic Variation Regulating Cellular Susceptibility to Zika Virus
Xie, X. (PI)
Duke University ( Award #1R21AI18549801)
6/1/24 → 4/30/25
Project: Research project
-
Testing inhibitors against flaviviruses
Xie, X. (PI)
Integer Bioscience ( Award # )
4/15/24 → 12/31/25
Project: Research project
-
SAVE Variant Pipeline-SARS-CoV-2 variants serum neutralization analysis
Xie, X. (PI)
American Type Culture Collection ( Award #AT002015)
9/26/23 → 9/25/28
Project: Research project
-
Inhibitory activities of compounds against flaviviruses
Xie, X. (PI)
Gilead Sciences, Inc ( Award # )
3/2/23 → 12/1/25
Project: Research project
-
Involving the testing of compounds against SARS-CoV-2
Xie, X. (PI)
Atea Pharmaceuticsl, Inc ( Award # )
10/25/22 → 12/31/25
Project: Research project
-
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old
Diya, O., Gayed, J., Lowry, F. S., Ma, H., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Cutler, M., Belanger, T., Cooper, D., Xu, X., Koury, K., Türeci, Ö., Şahin, U., Swanson, K. A., Modjarrad, K., Anderson, A. S. & Gurtman, A. & 1 others, , Apr 11 2025, In: Vaccine. 52, 126869.Research output: Contribution to journal › Article › peer-review
Open Access -
Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses
Qiao, W., Xie, X., Shi, P.-Y., Ooi, Y. S. & Carette, J. E., Feb 25 2025, In: Proceedings of the National Academy of Sciences of the United States of America. 122, 8, e2421573122.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity
Wang, B., Xia, H., Peng, B. H., Choi, E. J., Tian, B., Xie, X., Makino, S., Bao, X., Shi, P. Y., Menachery, V. & Wang, T., Jan 2025, In: Antiviral research. 233, 106059.Research output: Contribution to journal › Article › peer-review
-
Cell-Type-Specific Effect of Innate Immune Signaling on Stress Granules
Lamichhane, P. P., Aditi, Xie, X. & Samir, P., Sep 2024, In: Stresses. 4, 3, p. 411-420 10 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Sun, L., Ma, Y., Ma, X. R., Vulupala, V. R., Atla, S., Blankenship, L. R., Coleman, D., Xie, X., Neuman, B. W., Liu, W. R. & Xu, S., Apr 25 2024, In: Journal of medicinal chemistry. 67, 8, p. 6495-6507 13 p.Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations
Press/Media
-
Study Findings on COVID-19 Detailed by Researchers at University of Texas Medical Branch (TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication)
Endsley, J., Freiberg, A., Makino, S., Xie, X., Endsley, M., Terasaki, K. & Gonzalez Orozco, M.
12/17/24
1 item of Media coverage
Press/Media: Expert Comment